Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paroxetine effect on COAT-platelet production
NCT00229528Phase 4
Key facts
- Status
- Completed
- Start
- Mar 2004
- Primary completion
- May 2006
- Countries
- 1
- Sponsor
- University of Oklahoma
- Modality
- Small Molecules
- Drugs
- paroxetine
- Conditions
- coronary artery disease (CAD)
01
Overview
Phase 4, open-label trial of paroxetine in coronary artery disease (CAD) (2 arms), sponsored by University of Oklahoma. Primary endpoint: Percent COAT-platelet production. Started Mar 2004; status: completed.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
Normal Volunteers
Healthy volunteers receiving Paroxetine
CAD Patients
Patients with Coronary Artery Disease receiving Paroxetine
03
Who it enrols
Excludes patients with narrow angle glaucoma, active bleeding disorders, hyponatremia, seizure disorders, or recent (within 6 months) unstable angina or myocardial infarction.
04
Endpoints
Primary
Percent COAT-platelet production
Secondary
Percent COAT-platelet production
Beyond the preview
Go deeper on NCT00229528.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00229528.